A phase I, multicenter, open-label dose escalation study of LDK378, administered orally in adult patients with tumors characterized by genetic abnormalities in anaplastic lymphoma kinase (ALK)

Objective

Clinical trial of investigational drug LDK378 given by mouth.

IRB Protocol Number

11-0221

Principal Investigator(s)

ROSS CAMIDGE

Cancer Trials

• All Cancers

Sponsor(s)

Novartis

Contact

MARK MORROW at 720-848-0665
or MARK.MORROW@ucdenver.edu

Eligibility and Other Participant Information

What To Expect : A screening period to determine eligibility. A treatment period that can last as long as you are responding well to the study drug. A follow up period will consist of a clinic visit after you stop taking the study drug (to follow for any lasting side effects). // Eligibility criteria include but are not limited to 18 years or older with advanced solid tumor(s).